New assay to test KRAS mutations in ctDNA

In December 2018, the Molecular Diagnostics Lab is introducing a droplet digital PCR assay to monitor KRAS mutation in the circulating tumor DNA (ctDNA). The primary use of the test is for predicting recurrence and monitoring therapy of pancreatic ductal adenocarcinomas. The test requires 40 mls of EDTA anticoagulated blood that must be received in the laboratory the same day of the blood draw.